Clinical Advantra Z™

PRODUCT DESCRIPTION

The manufacturers of Advantra Z describe this product as an extract of citrus fruit that contains a family of adrenergic amines (predominantly beta-sympatomimetics, notably synephrine). These amines are reported to stimulate body metabolism and facilitate the utilization of energy substrates by the body. It is reported that such amines may enhance the uptake of amino acids into muscle and increase fat breakdown (lipolysis). Other described benefits of Advantra Z include possible hunger suppressant actions and mood enhancing effects. Advantra Z is the only patented form of Citrus aurantium that is sold as an adjunct to weight control and physical performance. Advantra Z has been used for more than one decade as a dietary supplement with a high degree of tolerability, overall safety and reported efficacy in some clinical studies (and in many consistent anecdotal reports). This information constitutes third party comments.

APPLICATIONS AS A DIETARY SUPPLEMENT

Advantra Z carries several patents and it has been used to attempt to cause the following actions on body structures and functions including: Stimulation of thermogenesis, Adjunctive weight reduction, Increases in the ratio of lean muscle to total body mass, Improvement in athletic performance, and appetite suppressant effects. The evidence-base for these effects appears to be emerging in contemporary literature, but differences in opinion may exist.

MECHANISMS OF ACTION

Advantra Z is believed to act by its principal content of p-synephrine. However, Advantra Z may contain other amines including: N-methyltyramine, Hordenine, Octopamine and Tyramine. Several controlled clinical observations of Advantra Z (alone or in combination) in humans have shown favorable outcome with the use of Advantra Z , which is believed to be superior in quality and more predictable in its actions than generic forms of Citrus aurantium. A residual medical opinion exists that Citrus aurantium could stimulate cardiovascular reflexes, but after more than one decade of use, there have been only isolated suggestions that cardiovascular toxicity can occur. There is no firm evidence of a direct causal relationship between heart attack or stroke risk and Advantra Z , but this hypothetical circumstance has been debated. In view of this residual doubt, Advantra Z should carry a reasonable warning.

There is a supposition that the amine contents of Advantra Z are less fat soluble than those found in Ma Huang/ephedra. It is proposed that the amines in Advantra Z do not regularly cross the blood brain barrier to an extent that may occur with ephedrine (ephedra/Ma Huang). Cumulative research implies that Advantra Z has an ability to preferentially stimulate the beta-3 cell receptors with much less impact on alpha 1,2 or beta 1,2 receptors. Pharmacokinetic and pharmacodynamic research on Citrus aurantium remains incomplete, a matter that impacts the use of many dietary supplements and some over-the-counter drugs. These suppositions have led to the proposal that Advantra Z may increase metabolic rate and favorably affect other body functions, without major or consistent effects on heart rate or blood pressure, in contrast to Ma Huang/ephedra. All medical professionals must understand the possibility of an idiosyncratic response to any dietary supplement or drug.

WARNING

A responsible warning for the sale of Advantra Z would be: To be used in states of health and to be avoided in the following circumstances: moderate or severe hypertension, individuals taking anti-hypertensive drugs, individuals with a history of abnormal heart rhythm or irregular heartbeat, individuals with narrow-angle glaucoma, individuals taking monoamine oxidase inhibitor drugs (MAOI), individuals taking cough and cold remedies that contain ephedrine related compounds, e.g. pseudoephedrine. Individuals taking any prescription medication must understand that bitter orange may interact with certain prescription drugs because it inhibits drug metabolizing enzyme systems. Inhibition of some drug metabolizing enzyme systems can result in increased concentration of certain levels of drugs in the blood.